The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence

Emmanouil Sinakos, Gennaro Selvaggi, Lavrentis Papalavrentios, Andreas Tzakis, Evangelos Akriviadis

Research output: Contribution to journalArticle

Abstract

Sorafenib is shown to improve survival in patients with advanced hepatocellular carcinoma (HCC). However, it has as yet not been tested in the liver transplantation (LT) setting. We report a 55-year-old man with multifocal HCC (stage B) related to hepatitis B virus cirrhosis (Child-Pugh B), initially treated with transarterial chemoembolization. After five months, sorafenib was added due to lack of response. This enhanced the downsizing of the tumor and eventually led to a surgically successful LT after 4 months of combined treatment. Sorafenib was re-initiated 15 months post-transplant due to skeletal tumor recurrence and led to patient's clinical improvement. The patient remains in good clinical condition 3 years after LT. Sorafenib was well tolerated throughout the entire period of administration with no serious or unexpected adverse events. We conclude that sorafenib can be safely used as a bridge to LT and in transplanted patients in case of HCC recurrence.

Original languageEnglish
Pages (from-to)228-230
Number of pages3
JournalAnnals of Gastroenterology
Volume24
Issue number3
StatePublished - Aug 12 2011

Fingerprint

Liver Transplantation
Hepatocellular Carcinoma
Recurrence
Neoplasms
Hepatitis B virus
Fibrosis
sorafenib
Transplants
Survival
Therapeutics

Keywords

  • Hepatocellular carcinoma
  • Liver transplantation
  • Sorafenib
  • Transarterial chemoembolization
  • Tumor recurrence

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence. / Sinakos, Emmanouil; Selvaggi, Gennaro; Papalavrentios, Lavrentis; Tzakis, Andreas; Akriviadis, Evangelos.

In: Annals of Gastroenterology, Vol. 24, No. 3, 12.08.2011, p. 228-230.

Research output: Contribution to journalArticle

Sinakos, Emmanouil ; Selvaggi, Gennaro ; Papalavrentios, Lavrentis ; Tzakis, Andreas ; Akriviadis, Evangelos. / The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence. In: Annals of Gastroenterology. 2011 ; Vol. 24, No. 3. pp. 228-230.
@article{e08558710c42445a8f9891c013f71aab,
title = "The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence",
abstract = "Sorafenib is shown to improve survival in patients with advanced hepatocellular carcinoma (HCC). However, it has as yet not been tested in the liver transplantation (LT) setting. We report a 55-year-old man with multifocal HCC (stage B) related to hepatitis B virus cirrhosis (Child-Pugh B), initially treated with transarterial chemoembolization. After five months, sorafenib was added due to lack of response. This enhanced the downsizing of the tumor and eventually led to a surgically successful LT after 4 months of combined treatment. Sorafenib was re-initiated 15 months post-transplant due to skeletal tumor recurrence and led to patient's clinical improvement. The patient remains in good clinical condition 3 years after LT. Sorafenib was well tolerated throughout the entire period of administration with no serious or unexpected adverse events. We conclude that sorafenib can be safely used as a bridge to LT and in transplanted patients in case of HCC recurrence.",
keywords = "Hepatocellular carcinoma, Liver transplantation, Sorafenib, Transarterial chemoembolization, Tumor recurrence",
author = "Emmanouil Sinakos and Gennaro Selvaggi and Lavrentis Papalavrentios and Andreas Tzakis and Evangelos Akriviadis",
year = "2011",
month = "8",
day = "12",
language = "English",
volume = "24",
pages = "228--230",
journal = "Annals of Gastroenterology",
issn = "1108-7471",
publisher = "Hellenic Society of Gastroenterology",
number = "3",

}

TY - JOUR

T1 - The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence

AU - Sinakos, Emmanouil

AU - Selvaggi, Gennaro

AU - Papalavrentios, Lavrentis

AU - Tzakis, Andreas

AU - Akriviadis, Evangelos

PY - 2011/8/12

Y1 - 2011/8/12

N2 - Sorafenib is shown to improve survival in patients with advanced hepatocellular carcinoma (HCC). However, it has as yet not been tested in the liver transplantation (LT) setting. We report a 55-year-old man with multifocal HCC (stage B) related to hepatitis B virus cirrhosis (Child-Pugh B), initially treated with transarterial chemoembolization. After five months, sorafenib was added due to lack of response. This enhanced the downsizing of the tumor and eventually led to a surgically successful LT after 4 months of combined treatment. Sorafenib was re-initiated 15 months post-transplant due to skeletal tumor recurrence and led to patient's clinical improvement. The patient remains in good clinical condition 3 years after LT. Sorafenib was well tolerated throughout the entire period of administration with no serious or unexpected adverse events. We conclude that sorafenib can be safely used as a bridge to LT and in transplanted patients in case of HCC recurrence.

AB - Sorafenib is shown to improve survival in patients with advanced hepatocellular carcinoma (HCC). However, it has as yet not been tested in the liver transplantation (LT) setting. We report a 55-year-old man with multifocal HCC (stage B) related to hepatitis B virus cirrhosis (Child-Pugh B), initially treated with transarterial chemoembolization. After five months, sorafenib was added due to lack of response. This enhanced the downsizing of the tumor and eventually led to a surgically successful LT after 4 months of combined treatment. Sorafenib was re-initiated 15 months post-transplant due to skeletal tumor recurrence and led to patient's clinical improvement. The patient remains in good clinical condition 3 years after LT. Sorafenib was well tolerated throughout the entire period of administration with no serious or unexpected adverse events. We conclude that sorafenib can be safely used as a bridge to LT and in transplanted patients in case of HCC recurrence.

KW - Hepatocellular carcinoma

KW - Liver transplantation

KW - Sorafenib

KW - Transarterial chemoembolization

KW - Tumor recurrence

UR - http://www.scopus.com/inward/record.url?scp=79961221146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961221146&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79961221146

VL - 24

SP - 228

EP - 230

JO - Annals of Gastroenterology

JF - Annals of Gastroenterology

SN - 1108-7471

IS - 3

ER -